{"result": {"id": "5960ee06-b809-4efc-8759-5bd7fdf1803a", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>PRIMARY ALDOSTERONISM<|>EVENT<|>A condition treated by MRAs like spironolactone, eplerenone, and finerenone, characterized by excessive aldosterone production.)  \n##  \n(\"entity\"<|>HEART FAILURE<|>EVENT<|>A medical condition treated by MRAs, particularly HFrEF (heart failure with reduced ejection fraction).)  \n##  \n(\"entity\"<|>CHRONIC KIDNEY DISEASE (CKD)<|>EVENT<|>A long-term condition treated by MRAs, with finerenone specifically approved for type 2 diabetes-related CKD.)  \n##  \n(\"entity\"<|>HYPERTENSION<|>EVENT<|>A cardiovascular condition treated by various medications, including MRAs and aprocitentan for resistant cases.)  \n##  \n(\"entity\"<|>RESISTANT HYPERTENSION<|>EVENT<|>A severe form of hypertension treated with aprocitentan when standard therapies fail.)  \n##  \n(\"entity\"<|>HYPERKALEMIA<|>EVENT<|>A potential adverse effect of MRAs, particularly spironolactone, mitigated by finerenone.)  \n##  \n(\"entity\"<|>TYPE 2 DIABETES<|>EVENT<|>A metabolic disorder often comorbid with CKD, for which finerenone provides cardiorenal protection.)  \n##  \n(\"relationship\"<|>PRIMARY ALDOSTERONISM<|>MRA<|>MRAs are used to treat primary aldosteronism.<|>8)  \n##  \n(\"relationship\"<|>HEART FAILURE<|>MRA<|>MRAs improve outcomes in heart failure, especially HFrEF.<|>8)  \n##  \n(\"relationship\"<|>CHRONIC KIDNEY DISEASE (CKD)<|>MRA<|>MRAs like finerenone are used to treat CKD.<|>8)  \n##  \n(\"relationship\"<|>HYPERTENSION<|>MRA<|>MRAs are used as fourth-line therapy for hypertension.<|>7)  \n##  \n(\"relationship\"<|>RESISTANT HYPERTENSION<|>APROCITENTAN<|>Aprocitentan is specifically approved for resistant hypertension.<|>9)  \n##  \n(\"relationship\"<|>HYPERKALEMIA<|>SPIRONOLACTONE<|>Spironolactone may cause hyperkalemia, a risk reduced by finerenone.<|>7)  \n##  \n(\"relationship\"<|>TYPE 2 DIABETES<|>FINERENONE<|>Finerenone is approved for cardiorenal protection in type 2 diabetes with CKD.<|>9)  \n##  \n(\"relationship\"<|>FINERENONE<|>HYPERKALEMIA<|>Finerenone has a better safety profile regarding hyperkalemia compared to spironolactone.<|>8)  \n##  \n(\"relationship\"<|>APROCITENTAN<|>RESISTANT HYPERTENSION<|>Aprocitentan is the only approved dual endothelin receptor antagonist for resistant hypertension.<|>9)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558662, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 720, "prompt_tokens": 3429, "total_tokens": 4149, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3328}, "prompt_cache_hit_tokens": 3328, "prompt_cache_miss_tokens": 101}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �为首个上市的非甾体 MRA,通过其侧 链使 MR的构象发生改变 , 与 MR蛋白稳定结合 ,具 有高 MR选择性、高 MR亲和力的特点[290-291]  。该药 对雄激素、糖皮质激素、孕酮和雌激素受体的亲和力较 低 ,故可明显减少不良事件发生率。\n　　　MRA主要用于原发性醛固酮增多症、心力衰竭 和 CKD的治疗 。有些高血压患者可能存在与醛固酮 相对过量相关的不同发病机制 ,并且与难治性高血压 的发生和发展明确相关 。可以使用螺内酯作为四线药 物给予治疗 ,其疗效优于 α 和 β受体阻滞剂[292]  ,不能 耐受者可选择依普利酮[293] 。非奈利酮可有效降低 CKD合并难治性高血压患者的收缩压 , 比螺内酯在高 钾血症方面的安全性更好。\n　　螺内酯和依普利酮都能降低 HFrEF患者的心血 管疾病死亡率以及心力衰竭恶化住院率[128] 。非奈利 酮在心脏和肾脏之间有均衡的组织分布 , 使其改善 CKD的预后比甾体类 MRA更具优势[294] 。多项研究 证实在标准治疗基础上 ,非奈利酮较安慰剂显著改善 CKD合并糖尿病患者的心肾结局 ,并获批准用于 2型 糖尿病合并 CKD患者的心肾保护[295] 。\n　　　依 普 利 酮、非 奈 利 酮 主 要 经 CYP3A4 代 谢。 MRA不宜与补钾或保钾利尿剂(阿米洛利、氨苯蝶  啶)联用。\n　　　(10) 内皮素双受体拮抗剂 : 内皮素双受体拮抗剂 是全新一类降压药 , 可抑制内皮素-1(endothelin-1, ET-1) 与 ETA 受体结合 ,发挥扩张血管和降低血压的 作用 ; 同时可抑制 ET-1与 ETB 受体结合 ,降低血管通 透性 ,进而在一定程度上避免水潴留[296] 。\n　　　阿普昔腾坦(Aprocitentan) 是目前国际上唯一被 批准上市的内皮素双受体拮抗剂 ,用于现有降压药难 以控制的成人高血压患者 。该药口服后血药浓度 3~ 4 h达峰 ,血浆半衰期长达 41.3~46.8 h, 因此可以每 日 1次服药[296] 。\n　　　阿普昔腾坦 Ⅲ期临床试验[297] 入选服用包括利尿 剂在内的 3种降压药后收缩压仍在 140 mmHg及以 上的难治性高血压患者 ,结果显示第 4周时阿普昔腾 坦 12.5 mg和 25mg的降压效果均优于安慰剂 ,阿普 昔腾坦 25mg在第 40周时持续降压有效 。 阿普昔腾 坦耐受性良好 ,最常见的不良事件是轻中度水肿或水 潴留。\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>MRA<|>ORGANIZATION<|>MRA is a non-steroidal mineralocorticoid receptor antagonist used for treating primary aldosteronism, heart failure, and chronic kidney disease (CKD). It has high selectivity and affinity for the mineralocorticoid receptor (MR) and low affinity for androgen, glucocorticoid, progesterone, and estrogen receptors, reducing adverse events.)  \n##  \n(\"entity\"<|>SPIRONOLACTONE<|>ORGANIZATION<|>Spironolactone is a steroidal MRA used as a fourth-line treatment for hypertension, particularly in cases related to aldosterone excess. It is effective but may cause intolerable side effects, leading to alternatives like eplerenone.)  \n##  \n(\"entity\"<|>EPLERENONE<|>ORGANIZATION<|>Eplerenone is a steroidal MRA metabolized by CYP3A4, used as an alternative to spironolactone for patients who cannot tolerate the latter. It improves cardiovascular outcomes in heart failure with reduced ejection fraction (HFrEF).)  \n##  \n(\"entity\"<|>FINERENONE<|>ORGANIZATION<|>Finerenone is a non-steroidal MRA with balanced tissue distribution between heart and kidneys, offering better safety in hyperkalemia compared to spironolactone. It is approved for cardiorenal protection in type 2 diabetes with CKD.)  \n##  \n(\"entity\"<|>APROCITENTAN<|>ORGANIZATION<|>Aprocitentan is the only approved dual endothelin receptor antagonist for resistant hypertension. It inhibits ET-1 binding to ETA and ETB receptors, reducing blood pressure and vascular permeability. It has a long half-life, allowing once-daily dosing.)  \n##  \n(\"entity\"<|>CYP3A4<|>ORGANIZATION<|>CYP3A4 is a metabolic enzyme involved in the breakdown of drugs like eplerenone and finerenone.)  \n##  \n(\"entity\"<|>ET-1<|>ORGANIZATION<|>Endothelin-1 (ET-1) is a peptide that binds to ETA and ETB receptors, influencing vascular tone and permeability. Its inhibition by aprocitentan helps lower blood pressure.)  \n##  \n(\"relationship\"<|>MRA<|>SPIRONOLACTONE<|>Spironolactone is a type of MRA used for hypertension and heart failure.<|>7)  \n##  \n(\"relationship\"<|>MRA<|>EPLERENONE<|>Eplerenone is a type of MRA used as an alternative to spironolactone.<|>7)  \n##  \n(\"relationship\"<|>MRA<|>FINERENONE<|>Finerenone is a non-steroidal MRA with advantages over steroidal MRAs like spironolactone and eplerenone.<|>8)  \n##  \n(\"relationship\"<|>EPLERENONE<|>CYP3A4<|>Eplerenone is metabolized by CYP3A4.<|>6)  \n##  \n(\"relationship\"<|>FINERENONE<|>CYP3A4<|>Finerenone is metabolized by CYP3A4.<|>6)  \n##  \n(\"relationship\"<|>APROCITENTAN<|>ET-1<|>Aprocitentan inhibits ET-1 binding to its receptors, reducing blood pressure.<|>9)  \n##  \n(\"relationship\"<|>SPIRONOLACTONE<|>EPLERENONE<|>Both are MRAs, but eplerenone is used when spironolactone is not tolerated.<|>6)  \n##  \n(\"relationship\"<|>FINERENONE<|>SPIRONOLACTONE<|>Finerenone offers better safety in hyperkalemia compared to spironolactone.<|>7)  \n##  \n(\"relationship\"<|>FINERENONE<|>EPLERENONE<|>Finerenone is a non-steroidal MRA, while eplerenone is a steroidal MRA.<|>6)  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_a38073d66faabbff309f294e10504735b1905c8ee0dbaa08ee6f1e1b825dd309_v2"}